Skip to main content
Equibles
ACXP logo

ACXP · Acurx Pharmaceuticals, Inc.

Track ACXP — free

Use ACXP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ACXP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.40 -0.09 (-5.74%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These matters raise substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$7.35M
Shares
5.27M

Acurx Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Acurx Pharmaceuticals, Inc. (ACXP) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-14
Second Quarter Financial Results Conference Call
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Acurx Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone ibezapolstat (IBZ) clinical program and efficacy Microbiome and recurrence mechanism Phase III and FDA pathway strategy
Diluted EPS
$-0.62
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Acurx Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Positive tone Microbiome-Sparing Mechanism / Class Effect Ibezapolstat Phase 3 Funding and Strategy Regulatory Designations and FDA Interactions
Diluted EPS
$-1.23
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Acurx Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Positive tone Ibezapolstat Phase IIb data and Phase III readiness Financing and capital raising Partnerships and government funding
Diluted EPS
$-1.89
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Acurx Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Positive tone Microbiome Differentiation and Publications Ibezapolstat Phase 3 Program and Funding Lancet Microbe Publication
Diluted EPS
$-2.15
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Acurx Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Positive tone Ibezapolstat (IBZ) Phase 3 readiness Clinical data and scientific publications Financing and capital raises
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Acurx Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone Ibezapolstat Phase III readiness C. difficile clinical results and anti-recurrence data Intellectual property and patents
Diluted EPS
$-3.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
Acurx Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone Ibezapolstat Phase 3 readiness and clinical progress Intellectual property and microbiome patent Financial position and cash runway
Diluted EPS
$-5.21
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Acurx Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone Phase 3 readiness and FDA alignment Ibezapolstat clinical and microbiology data Phase 3 cost and funding
Diluted EPS
$-5.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-18
Acurx Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone Phase III Clinical Trial Planning Ibezapolstat Phase IIb Clinical Data FDA Regulatory Pathway
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Acurx Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-4.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Acurx Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-5.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Acurx Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-5.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Acurx Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Acurx Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-6.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Acurx Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-5.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Acurx Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-5.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-17
Acurx Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-16
Acurx Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-9.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Acurx Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-11.40
Audio Transcript Slides 8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts CIK 1736243 CUSIP 00510M203 13F (30d) 20 filings 20 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)